129 related articles for article (PubMed ID: 11528191)
1. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.
Jakse G; Hall R; Bono A; Höltl W; Carpentier P; Spaander JP; van der Meijden AP; Sylvester R
Eur Urol; 2001 Aug; 40(2):144-50. PubMed ID: 11528191
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
[TBL] [Abstract][Full Text] [Related]
4. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
5. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
Mugiya S; Ozono S; Nagata M; Takayama T; Ito T; Maruyama S; Hadano S; Nagae H
Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
[TBL] [Abstract][Full Text] [Related]
7. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.
Witjes JA; v d Meijden AP; Collette L; Sylvester R; Debruyne FM; van Aubel A; Witjes WP
Urology; 1998 Sep; 52(3):403-10. PubMed ID: 9730451
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
10. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
[TBL] [Abstract][Full Text] [Related]
12. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
13. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
Griffiths TR; Charlton M; Neal DE; Powell PH
J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
15. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
16. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
Losa A; Hurle R; Lembo A
J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
[TBL] [Abstract][Full Text] [Related]
17. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Järvinen R; Kaasinen E; Rintala E; Group TF
Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
[TBL] [Abstract][Full Text] [Related]
20. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder].
Tsukagoshi S
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]